Participated in Tulane's acclaimed equity research program. Collaborated with a team of three other analysts to cover First Bancshares Inc (NASDAQ: FBMS). Co-authored a research report, included in the projects section of my profile, which is published on the Burkenroad website.

X-Bolt is an emerging innovator of orthopedic devices. Its first product, Pro-X1 Trochanteric Nail, received FDA market clearance and is projected to commercialize in the U.S. market in Q4 2023.As a Finance Intern, I worked on a broad range of projects including the preparation of financialstatements, forecasting future inventory and cash flows, R&D cost analysis, Inventory management, tax benefit analysis and market research for potential venture capital firms to target in X-bolt's Series A funding. I presented findings to senior X-Bolt leadership and participated in investor meetings and internal planning sessions.

Took orders, served food/beverages, and maintained cleanliness in the bakery to ensure customer satisfaction.